Navigation Links
Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Date:2/15/2008

rcialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms - GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at http://www.cellgenesys.com.

Statements made herein about the company, other than statements of historical fact, including statements about potential association between immune response and patient survival, about the company's progress, results, analysis, and timing of VITAL-1 and VITAL-2 and other clinical trials and preclinical programs and the nature of product pipelines are forward-looking statements. and These statements are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including the risk that the Phase 3 trials do not confirm the Phase 2 findings regarding potential association between immune response and patient survival as well as risks associated with the success of clinical trials and research and development programs, regulatory requirements and the regulatory approval process for clinical trials, manufacture and commercialization of the company's products, competitive technologies and products, patents, the need for and reliance on partnerships with third parties, and the need for additional financings. For information about these and other risks
'/>"/>

SOURCE Cell Genesys, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
2. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
3. CEL-SCI Corporation Reports First Quarter Financial Results
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
6. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
7. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
8. Study Reports Successful Cloning of Human Embryo Using Adult DNA
9. Schering-Plough Reports Top-Line Results of the IDEAL Study
10. Second Thoughts about Fluoride, Reports Scientific American
11. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)...   Vittamed Corporation , a neurodiagnostics medical device company ... T. (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, ... " Teo Forcht Dagi is an ... and venture capital," said Remis Bistras , President and ... clinical, strategic, and entrepreneurial expertise to our Board." ...
(Date:8/29/2014)... WASHINGTON , Aug. 29, 2014 Diseases ... a generation ago are returning. Measles was declared ... cases in 2014 as of August 15—the highest incidence ... public health department declared whooping cough a problem ... children are getting sick and dying from these preventable ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will ... the Australian and New Zealand Forensic Science Society,s ... Sciences in Adelaide, Australia . ... concerning the advancements that hyperspectral imaging can bring ... Jeffrey Beckstead , Director of Product Development at ...
Breaking Medicine Technology:Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... leading Clinical Research Organization, will exhibit at the 61st ... Liver Diseases, The Liver Meeting®, being held 30 October ... Representatives from PRA,s Infectious Diseases Research Center and ... discuss our expertise in hepatitis B & C as ...
... ANN ARBOR, Mich., Oct. 28 Adeona Pharmaceuticals, Inc., (AMEX: ... hold its Annual Shareholders Meeting on Tuesday, November 2, from ... 3930 Varsity Drive, Ann Arbor, MI, 48108. ... S. Kuo, M.D., M.B.A., will give an update on the ...
Cached Medicine Technology:PRA International to Exhibit at Liver Diseases Conference 2
(Date:9/1/2014)... Ontraport , one of the latest ... to automate the small intricacies of managing an online ... prompting an investigative review. , “As a new ... all of the small details involved with running a ... “That’s why Ontraport has become so popular in this ...
(Date:9/1/2014)... Pastor Thompson is an ordained minister and ... He is a licensed minister through the Church of the ... years in New Mexico, Colorado and North Dakota. He and ... year. He also has two beautiful daughters, Brianna, 22 ... Ministry from Nazarene Bible College, in Colorado Springs and is ...
(Date:9/1/2014)... 2014 This Flash Report ... perspectives on stakeholder management needs ... flash report to speak with Heartbeat Experts ... product:, ,     Position clinically meaningful ... market ,     Understanding stakeholder interactions with ...
(Date:8/31/2014)... (PRWEB) August 31, 2014 The FDA ... Nutrition Facts label. If adopted, the proposed changes would ... addition of “added sugars” on the label, and a ... to keep “added sugars” off the label. NutriGold fully ... consumers make healthier food choices. “After 20 years, it's ...
(Date:8/31/2014)... Mesa, Arizona (PRWEB) August 31, 2014 For ... ragweed is likely the culprit. Ragweed is the most common ... percent of Americans. , The most common symptoms of ragweed ... and throat, and sneezing. Ragweed allergy can also lead to ... ragweed allergies should consult an allergist about allergy immunotherapy - ...
Breaking Medicine News(10 mins):Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Diabetes Products 2Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 2Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 3Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 4Health News:AllergyEasy Announces Success Helping Patients Build Immunity To Autumn Ragweed Pollens With Under-the-tongue Drops 2Health News:AllergyEasy Announces Success Helping Patients Build Immunity To Autumn Ragweed Pollens With Under-the-tongue Drops 3
... to really pan out, expert warns , , THURSDAY, June 26 ... an immune response to an investigational vaccine lived twice as ... research shows. , "If you were an immune responder, you ... Dr. Susan Domchek, an associate professor of medicine at the ...
... Superior Efficacy to Avastin at Improving Visual Acuity When, ... Percent Patient Share, ... from Decision Resources, WALTHAM, Mass., June 26 ... firms focusing on pharmaceutical and,healthcare issues, finds that Genentech/Novartis,s ...
... MINNEAPOLIS, June 26 ACM today announced ... Bryngelson as the company,s new,Executive Vice President ... development, operations, and client service management, Ms.,Bryngelson ... components of,ACM,s infrastructure -- including technology, call ...
... Home Medical,Equipment, Inc. (Pink Sheets: SHMM) announced today ... has completed its seventh,staffing agreement and is aggressively ... and CEO of parent company Southern Home Medical,stated, ... team has far,exceeded their own expectations in their ...
... 26 "The time is right and the,wording is ... "This bill recognizes the God-given Right to Life of ... will end the slaughter of,innocent children.", S.3111, introduced ... is scheduled for debate in the Senate Committee on ...
... Therapeutics (Prime),announced today the hiring of Jerry Steffl ... for developing Prime,s position on,policy issues at both ... approach to government affairs both internally and with ... Prime,s lobbying,efforts with industry associations and trade groups, ...
Cached Medicine News:Health News:Breast Cancer Vaccines Look Promising 2Health News:Breast Cancer Vaccines Look Promising 3Health News:Because of Its Ability to Generate Higher Total Sales in the United States and Europe, Lucentis Will Earn Clinical Gold Standard Status by 2011 for the Treatment of Diabetic Retinopathy 2Health News:ACM Adds Top Industry Executive to Its Leadership Team 2Health News:Encore Medical Staffing of Greenville Signs Seventh Staffing Agreement 2
Irrigation pump for arthroscopy....
... in Arthroscopy. Ease of use and superior ... the 10k Fluid System unique. , ,The ... maintains intra-articular pressure, while providing instantaneous flow ... when used for Laparoscopy, provides instantaneous fluid ...
... CD / DVD Burner captures still ... to 50 patient archives allows for ... future retrieval. The unit provides software ... for easy playback and editing. Compatible ...
... The new MicroLux® Digital Video Recorder gives you ... and store your surgical cases. THE DVR is ... life-like presentations. With its convenient mouse and footswitch, ... procedure you need - no more hours of ...
Medicine Products: